Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Centessa PharmaceuticalsCNTA 12 PB Ratio is 12.86 as of Jul. 14, 2026, which is 161% above its 10-year median of 4.92. GuruFocus rates CNTA with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 1,228 Biotechnology companies, Centessa Pharmaceuticals ranks worse than 89.33% on this metric.
Centessa Pharmaceuticals PLC stock PB Ratio (=12.86) is close to 3-year high of 13.33.
The historical rank and industry rank for Centessa Pharmaceuticals's PB Ratio or its related term are showing as below:
CNTA'
s PB Ratio Range Over the Past 10 Years
Min: 2.81 Med: 4.92 Max: 13.33
Current: 12.86
During the past 7 years, Centessa Pharmaceuticals's highest PB Ratio was 13.33. The lowest was 2.81. And the median was 4.92.
CNTA's PB Ratio is ranked worse than 89.33% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs CNTA: 12.86
During the past 12 months, Centessa Pharmaceuticals's average Book Value Per Share Growth Rate was 8.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Centessa Pharmaceuticals was -0.10% per year. The lowest was -17.90% per year. And the median was -9.00% per year.
Back to Basics: PB Ratio
Centessa Pharmaceuticals (NAS:CNTA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Centessa Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Centessa Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Centessa Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Centessa Pharmaceuticals (CNTA) has a PB Ratio of 12.86 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Centessa Pharmaceuticals and its competitors. This is 161% above median its historical median of 4.92. Over the past decade, Centessa Pharmaceuticals' PB Ratio has ranged from 2.81 to 13.33. According to the industry distribution chart, Centessa Pharmaceuticals ranks #1097 out of 1228 companies in the Biotechnology industry, placing it in the top 89.3%.
Is Centessa Pharmaceuticals' PB Ratio too high?
Centessa Pharmaceuticals' current PB Ratio of 12.86 is 161% above median its 10-year median of 4.92. Over the past 10 years, this metric has ranged from a low of 2.81 to a high of 13.33. The Biotechnology industry median PB Ratio is 2.89. Centessa Pharmaceuticals' value of 12.86 is 345.8% above this industry median. Based on the distribution chart, Centessa Pharmaceuticals ranks #1097 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Centessa Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centessa Pharmaceuticals' PB Ratio compare to CGON and LGND?
According to the Biotechnology industry distribution chart, Centessa Pharmaceuticals ranks #1097 out of 1228 companies for PB Ratio. This places Centessa Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 2.89. Centessa Pharmaceuticals' value of 12.86 is 345.8% above this benchmark. Historically, Centessa Pharmaceuticals' own PB Ratio has ranged from 2.81 to 13.33 over the past decade. While the company's 10-year median is 4.92 vs. the industry median of 2.89, Centessa Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Centessa Pharmaceuticals's current PB Ratio of 12.86 is 345.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Centessa Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Centessa Pharmaceuticals's current PB Ratio is 12.86, which is 161% above median its own 10-year median of 4.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centessa Pharmaceuticals stock overvalued right now?
Centessa Pharmaceuticals (CNTA) has a current PB Ratio of 12.86. The current PB Ratio is 12.86, which is 161% above median its 10-year median of 4.92 and 345.8% above the Biotechnology industry median of 2.89. Centessa Pharmaceuticals' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Centessa Pharmaceuticals (CNTA), the current PB Ratio is 12.86 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
12GF Score
Get the complete analysis for CNTA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNTA has been successfully added to your 
